Individuals with treatment-resistant depression do not achieve and sustain remission after multiple pharmacotherapies, with an unknown impact on employment. This study investigates the expenditures of TRD from a private-payer perspective in Canada.
Joseph Zingaro, BSc Phm
Advertisement
Articles by Joseph Zingaro, BSc Phm
Advertisement
Latest Updated Articles
- Private-payer Costs for Employees with Treatment-resistant Depression
Published: August 18th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Breaking News: CVS Buys Rite Aid, Bartell Drugs
2
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
3
FDA Approves 1-Minute HIV Self-Test
4
Young Women With Symptomatic Long COVID At Higher Risk of POTS
5
